Last edition
News about "Innovent Biologics"
Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies
As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.
Innovent Biologics | 05/12/2025 | By Dineshwori
Innovent's PECONDLE Becomes China's First Approved IL-23p19 Antibody
Innovent has received NMPA approval for PECONDLE (picankibart injection), marking China’s first IL-23p19 monoclonal antibody to be cleared for treating moderate-to-severe plaque psoriasis in adults eligible for systemic therapy.
Innovent Biologics | 02/12/2025 | By Dineshwori
Innovent Gets Second Fast Track Designation from FDA for IBI363
This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy.
Innovent Biologics | 17/02/2025 | By Aishwarya | 249
Innovent's DOVBLERON Secures Second NMPA Approval for ROS1-Positive NSCLC
China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON®, a next-generation ROS1 tyrosine kinase inhibitor (TKI).
Innovent Biologics | 03/01/2025 | By Abha | 241
Mankind Pharma, Innovent Biologics to Commercialize Sintilimab for Cancer Care
This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.
Innovent Biologics | 27/12/2024 | By Aishwarya | 303
Innovent Partners with Ask Pharm for Limertinib for Treatment of Lung Cancer
Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib in mainland China, and will be entitled to receive a commercialization service fee based on the product's net sales in the region.
Innovent Biologics | 08/10/2024 | By Aishwarya | 464
Innovent Secures Fast Track Designation from FDA for IBI363
Innovent Biologics has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to its PD-1/IL-2α Bispecific Antibody Fusion Protein for the treatment of unresectable locally advanced or metastatic melanoma.
Innovent Biologics | 04/09/2024 | By Aishwarya | 535
Innovent and WeComput to Accelerate AI-Driven Drug Discovery and Development
Innovent Biologics, Inc. has forged a strategic partnership with WeComput to jointly advance the construction and improvement of Innovent Biologics' Artificial Intelligence for Drug Discovery platform.
Innovent Biologics | 26/07/2024 | By Aishwarya | 338
Innovent Signs Agreement with IASO Bio for Cell Therapy
Innovent Biologics, Inc. and IASO Biotechnology have signed an agreement on a series of cooperation, including IASO Bio's purchase from Innovent regarding its relevant right of FUCASO (Equecabtagene Autoleucel) and obtaining license from Innovent regarding the intellectual property related to FUCASO, as well as Innovent's equity investment in IASO Bio.
Innovent Biologics | 06/07/2024 | By Aishwarya | 558
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy